Observational studyJournal of neurology2025

A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II).

Piero Barbanti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.